| Literature DB >> 28950862 |
Edwin Michael1, Brajendra K Singh2, Benjamin K Mayala2, Morgan E Smith2, Scott Hampton3, Jaroslaw Nabrzyski3.
Abstract
BACKGROUND: There are growing demands for predicting the prospects of achieving the global elimination of neglected tropical diseases as a result of the institution of large-scale nation-wide intervention programs by the WHO-set target year of 2020. Such predictions will be uncertain due to the impacts that spatial heterogeneity and scaling effects will have on parasite transmission processes, which will introduce significant aggregation errors into any attempt aiming to predict the outcomes of interventions at the broader spatial levels relevant to policy making. We describe a modeling platform that addresses this problem of upscaling from local settings to facilitate predictions at regional levels by the discovery and use of locality-specific transmission models, and we illustrate the utility of using this approach to evaluate the prospects for eliminating the vector-borne disease, lymphatic filariasis (LF), in sub-Saharan Africa by the WHO target year of 2020 using currently applied or newly proposed intervention strategies. METHODS ANDEntities:
Keywords: Data discovery; Data-driven parasite transmission modeling; Hierarchical modeling; Lymphatic filariasis; Mass drug administration; Neglected tropical diseases; Parasite elimination programs; Parasite transmission heterogeneity; Scientific computational discovery of knowledge; Spatial scale; Sub-Saharan Africa; Vector control; Vector-borne diseases
Mesh:
Year: 2017 PMID: 28950862 PMCID: PMC5615442 DOI: 10.1186/s12916-017-0933-2
Source DB: PubMed Journal: BMC Med ISSN: 1741-7015 Impact factor: 8.775
Fig. 1Mapped inputs for modeling the baseline transmission dynamics and effects of interventions against lymphatic filariasis (LF) in sub-Saharan Africa. a A smooth map of the estimates of LF prevalence is shown. The map was created using a multivariate Bayesian generalized linear spatial model, as described in [44]. b Smooth maps of the annual biting rates (ABRs) of Anopheles and Culex mosquitoes were created by simple kriging of ABR data obtained from literature searches and public databases (e.g., the Malaria Atlas Project (MAP)/Malaria Risk in Africa (MARA) databases). The observed data points are also shown. The Culex distribution is patchier than that of Anopheles, so we consider the Anopheles model to apply wherever Anopheles mosquitoes are implicated in transmission (Table 1). Only in those areas where Anopheles mosquitoes are not implicated at all did we use the Culex model. Note, however, that given the sparseness of the ABR data as shown on the map, we used model-estimated ABR values in the modeling exercise described in the text (see Methods). c Country-level coverages of bed nets (i.e., insecticide-treated nets (ITNs) interpolated from Admin1 data. Smoothed annual maps were developed for 2000–2012; here we show data for years 2000, 2007, and 2012
Details of annual mass drug administration (MDA) delivery in LF endemic sub-Saharan African countries
| Countrya | Vector genusb | MDA type | IUs (initial phase: 1–3 years) | Start year | % program drug coverage (range) | IUs (expansion phase: 4–5 years) | Start year | % program drug coverage (range) | IUs (later phase) | Start year | % program drug coverage (range) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Benin |
| IVM-ALB | 9 | 2002 | 79.35 (77.8–80.5) | 21 | 2004 | 81.23 (75.4–85.6) | 25 | 2013 | 100 |
| Burkina Faso |
| IVM-ALB | 22 | 2001 | 74.43 (68.4–77.8) | 59 | 2005 | 80.3 (77.2–81.8) | 57 | 2013 | 71.4 |
| Cameroon |
| IVM-ALB | 12 | 2008 | 75.95 (74.6–77.3) | 84 | 2010 | 73.9 (69.8–78.0) | 123 | 2012 | 80.35 (79.9–80.8) |
| Comoros |
| DEC-ALB | 2 | 2001 | 73.2 (56.9–85.7) | – | – | – | – | – | – |
| Congo |
| IVM-ALB | – | – | – | – | – | – | 5 | 2013 | 92.8 |
| Cote d’Ivoire |
| IVM-ALB | 3 | 2009 | 78.9 | 13 | 2010 | 31.5 | 5 | 2013 | 70 |
| Egypt |
| DEC-ALB | 28 | 2000 | 93.92 (91.0–96.7) | – | – | – | – | – | – |
| Ethiopia |
| IVM-ALB | 5 | 2009 | 77.53 (72.7–81.7) | – | – | – | 27 | 2012 | 76.4 (74.2–78.6) |
| Ghana |
| IVM-ALB | 22 | 2000 | 62.28 (23.9–74.1) | 66 | 2005 | 72.15 (63.9–75.2) | 91 | 2013 | 76.8 |
| Guinea Bissau |
| IVM-ALB | – | – | – | – | – | – | 33 | 2011 | 71.7 (69.4–74.0) |
| Kenya |
| DEC-ALB | 1 | 2002 | 81.20 | 3 | 2003 | 71.5 (62.7–79.5) | 9 | 2011 | 58.3 |
| Liberia |
| IVM-ALB | – | – | – | – | – | – | 13 | 2012 | 90.7 (81.1–100) |
| Madagascar |
| DEC-ALB | 3 | 2005 | 81.40 | 25 | 2006 | 76.68 (74.6–79.5) | 39 | 2010 | 66.53 (66.3–66.9) |
| Malawi |
| IVM-ALB | 9 | 2008 | 80.50 | – | – | – | 26 | 2009 | 81.68 (79.8–83.0) |
| Mali |
| IVM-ALB | 9 | 2005 | 80.70 (78.2–83.2) | 46 | 2007 | 78.75 (61.6–85.1) | 45 | 2013 | 82.10 |
| Mozambique |
| IVM-ALB | 18 | 2009 | 71.81 | 51 | 2010 | 77.85 (74.4–81.3) | 94 | 2013 | 85 |
| Niger |
| IVM-ALB | 9 | 2007 | 72.20 | 20 | 2008 | 65.60 (58.7–72.5) | 30 | 2010 | 69.28 (63.7–72.7) |
| Nigeria |
| IVM-ALB | 14 | 2000 | 41.53 (32.3–53.7) | 31 | 2003 | 72.63 (64.2–77.1) | 135 | 2009 | 58.08 (48.9–73.6) |
| Senegal |
| IVM-ALB | 7 | 2007 | 73.60 (66.8–78.7) | – | – | – | 13 | 2013 | 49.3 |
| Sierra Leone |
| IVM-ALB | 6 | 2007 | 61.30 | 13 | 2008 | 72.1 (70.1–74.1) | 14 | 2010 | 79.5 (77.7–80.6) |
| Sudan |
| IVM-ALB | – | – | – | – | – | – | 2 | 2013 | 87.8 |
| Tanzania |
| IVM-ALB | 17 | 2000 | 76.10 (59.1–100.0) | 25 | 2003 | 70.54 (60.5–79.9) | 84 | 2011 | 73.03 (65.8–77.1) |
| Togo |
| IVM-ALB | 7 | 2000 | 67.20 | – | – | – | – | – | – |
| Uganda |
| IVM-ALB | 6 | 2002 | 66.80 (53.5–76.0) | 38 | 2007 | 67.5 (62.4–72.4) | 41 | 2012 | 66.9 (66.8–67.0) |
MDA was implemented across a country in a staggered manner, effectively creating several cohorts of implementation units (IUs), namely those that began to receive MDA in the initial phase, the expansion phase, or the later phase
aThe following countries not listed in the table had not yet started MDA as of 2015: Angola, Central African Republic, Chad, Democratic Republic of Congo, Djibouti, Equatorial Guinea, Gabon, Guinea, South Sudan, The Gambia, Zambia, and Zimbabwe
bVector genus information was retrieved from WHO [49]
IVM ivermectin, ALB albendazole, DEC diethylcarbamazine citrate
Modeled intervention scenarios
| Scenarios | MDA type | MDA coverage | VC coverage |
|---|---|---|---|
| MDA1 | Annual | CC | CC |
| MDA2 | Annual | CC | 80% |
| MDA3 | Annual | 80% | CC |
| MDA4 | Annual | 80% | 80% |
| Bi-MDA1 | Biannual | CC | CC |
| Bi-MDA2 | Biannual | CC | 80% |
| Bi-MDA3 | Biannual | 80% | CC |
| Bi-MDA4 | Biannual | 80% | 80% |
| IDA1 | Annual | CC | CC |
| IDA2 | Annual | CC | 80% |
| IDA3 | Annual | 80% | CC |
| IDA4 | Annual | 80% | 80% |
MDA-based LF interventions were simulated for the following 12 intervention scenarios where MDA represents the standard two-drug regimen (diethylcarbamazine-albendazole) delivered annually, Bi-MDA represents the standard two-drug regimen delivered biannually, and IDA represents a triple-drug regimen (ivermectin-diethylcarbamazine-albendazole) delivered annually. Each type of MDA is combined with vector control (VC) at either current (CC) or enhanced (80%) coverage
Fig. 2Modeling workflow and data inputs for the modeling analysis obtained from literature searches and publicly available databases. a The top schematic depicts the hierarchical modeling steps employed to quantify the expected impacts of MDA-based intervention programs to predict timelines to achieve the elimination of lymphatic filariasis (LF) from an endemic country. b The bottom diagram shows the steps, mainly involving geostatistical mapping, on how the data inputs required to initialize the LF model were obtained from several databases, either publicly available or created for this study from literature searches. Note that although we began examining the development of an ABR smooth map, the sparseness of ABR data precluded their reliable construction for use in this study. We instead used model fits to mf prevalence in a site to estimate ABR input values (see Methods)
Fig. 3Learning ensembles of local LF transmission models. a An example of baseline fits to three age profiles (boxes depicting mean prevalences predicted in each respective age class with the vertical lines showing the 95% confidence intervals of these means) derived for a site in the country of Senegal with overall mf prevalence of 32.1%. b The corresponding predictions of overall mf prevalence are shown in a histogram where the solid vertical line represents the known overall mf value and the dashed vertical line represents the median of the predicted distribution. c The predicted distribution of baseline annual biting rates (ABRs) from the fits to each age-infection profile is shown with the median indicated by a vertical dashed line. The inset plot zooms in on the distributions in the lower ABR region. d A cluster plot showing the relative contributions of each age-infection profile to the pooled fits across all modeled sites in Senegal. For this country, the plateau-type age-infection model contributed most to infection for the sampled sites, followed in importance by the convex and the linear age models
Fig. 4Histograms of breakpoints and threshold biting rates aggregated across modeled sites in a country. Solid vertical lines represent the mean value of the distribution, and dashed vertical lines represent the 5th and 95th percentile values, respectively. The histograms show that there is variation in transmission thresholds both within and between countries
Aggregated country-specific mf breakpoints
| Country | Mean mf breakpoint at TBR (5th and 95th percentiles) | Mean mf breakpoint at ABR (5th and 95th percentiles) |
|---|---|---|
| Angola | 0.516 (0.0435, 2.08) | 0.143 (0.015, 0.341) |
| Benin | 0.446 (0.0609, 1.96) | 0.148 (0.0289, 0.343) |
| Burkina Faso | 0.648 (0.0436, 2.74) | 0.155 (0.0163, 0.383) |
| Cameroon | 0.7 (0.0481, 3.01) | 0.188 (0.0182, 0.506) |
| Central African Republic | 0.719 (0.045, 3.02) | 0.176 (0.0172, 0.465) |
| Chad | 0.661 (0.0435, 2.88) | 0.153 (0.0165, 0.386) |
| Comoros | 0.759 (0.0306, 3.42) | 0.103 (0.00416, 0.304) |
| Congo | 0.958 (0.0482, 3.69) | 0.22 (0.02, 0.659) |
| Cote d’Ivoire | 0.327 (0.0438, 0.861) | 0.146 (0.0177, 0.337) |
| Democratic Republic of the Congo | 0.648 (0.0435, 2.57) | 0.221 (0.0159, 0.675) |
| Djibouti | 0.632 (0.0609, 2.44) | 0.178 (0.0216, 0.462) |
| Egypt | 0.345 (0.027, 1.62) | 0.118 (0.00596, 0.308) |
| Equatorial Guinea | 0.834 (0.044, 3.33) | 0.23 (0.017, 0.742) |
| Ethiopia | 0.372 (0.0432, 1.09) | 0.145 (0.0161, 0.333) |
| Gabon | 0.951 (0.0453, 3.73) | 0.238 (0.0197, 0.772) |
| Ghana | 0.267 (0.124, 0.482) | 0.158 (0.0661, 0.29) |
| Guinea | 0.308 (0.0402, 0.806) | 0.225 (0.0207, 1.1) |
| Guinea Bissau | 0.308 (0.0402, 0.806) | 0.225 (0.0207, 1.1) |
| Kenya | 0.584 (0.0432, 2.33) | 0.167 (0.0166, 0.422) |
| Liberia | 0.777 (0.0437, 3.31) | 0.189 (0.0173, 0.526) |
| Madagascar | 0.33 (0.0325, 1.29) | 0.0925 (0.00249, 0.233) |
| Malawi | 0.578 (0.0312, 2.84) | 0.0758 (0.0027, 0.218) |
| Mali | 0.799 (0.0438, 3.34) | 0.13 (0.0145, 0.302) |
| Mozambique | 0.799 (0.0438, 3.34) | 0.13 (0.0145, 0.302) |
| Niger | 0.547 (0.0497, 1.97) | 0.17 (0.0142, 0.484) |
| Nigeria | 0.652 (0.0449, 2.2) | 0.207 (0.0214, 0.758) |
| Senegal | 0.26 (0.0319, 0.642) | 0.0907 (0.0034, 0.2) |
| Sierra Leone | 0.563 (0.0366, 2.87) | 0.0929 (0.00366, 0.255) |
| South Sudan | 0.51 (0.0363, 2.64) | 0.0907 (0.00361, 0.245) |
| Sudan | 0.901 (0.0416, 3.49) | 0.188 (0.0175, 0.546) |
| Tanzania | 0.874 (0.0386, 3.51) | 0.224 (0.016, 0.689) |
| The Gambia | 0.802 (0.0439, 3.35) | 0.159 (0.0172, 0.405) |
| Togo | 0.61 (0.0417, 2.42) | 0.152 (0.0163, 0.38) |
| Uganda | 0.516 (0.0435, 2.08) | 0.143 (0.015, 0.341) |
| Zambia | 0.446 (0.0609, 1.96) | 0.148 (0.0289, 0.343) |
| Zimbabwe | 0.648 (0.0436, 2.74) | 0.155 (0.0163, 0.383) |
The mean (and 5th and 95th percentile) mf breakpoint values by country are given under annual biting rate (ABR) and threshold biting rate (TBR) conditions. Calculations using TBR apply for interventions including supplemental VC, while those using ABR apply for interventions without VC. The relevant vector model was used for each country as indicated in Table 1. For Kenya, Malawi, and Tanzania, the results from the culicine LF model are given, as Culex mosquitoes represent the dominant vector in these countries. For elimination analyses, the 5th percentile value represents the breakpoint value, the crossing of which corresponds to a 95% probability for achieving LF elimination
Fig. 5Patterns of elimination timelines of lymphatic filariasis (LF) by calendar years in sub-Saharan Africa. a An example of the effects of staggered annual MDA implementation in cohorts of implementation units (IUs) across a country on LF elimination trajectories, using data and model simulations for Kenya. The modeled decline in the overall mean microfilariae (mf) prevalence as a result of LF intervention is shown, where each cohort had a different MDA start year: 2001, 2003, 2011, and 2016, respectively. The elimination year for each cohort is shown by an open circle on the x-axis of the respective subplot. b Patterns in timelines to LF elimination based on annual MDAs provided to IUs either randomly or in a phased sequential manner starting with provision of treatments to the highest prevalence IUs first. The vertical bars show fractions of IUs in a country achieving LF elimination by calendar years. The results for sequential coverage of IUs are shown in orange (i.e., IUs with higher baseline endemicity receiving MDA earlier than lower endemicity IUs), and those for random coverage of IUs are shown in blue. The results for the random selection of IUs are more pessimistic than those for the sequential approach. Data on the years and number of IUs implementing annual MDA and drug coverages are from the WHO LF PCT databank. Future LF interventions were simulated for the current MDA and VC coverages for a given country
Comparison between random versus sequential selections of IUs for implementing delivery of annual MDAs
| Random | Sequential | |||
|---|---|---|---|---|
| 95% EP Th | WHO 1% | 95% EP Th | WHO 1% | |
| Angola | 2032 | 2020 | 2032 | 2020 |
| Benin | 2028 | 2019 | 2023 | 2018 |
| Burkina Faso | 2032 | 2022 | 2031 | 2018 |
| Cameroon | 2033 | 2023 | 2029 | 2018 |
| Central African Republic | 2033 | 2022 | 2033 | 2022 |
| Chad | 2033 | 2022 | 2033 | 2022 |
| Comoros | 2023 | 2010 | 2023 | 2010 |
| Congo | 2033 | 2022 | 2032 | 2020 |
| Cote d’Ivoire | 2029 | 2018 | 2028 | 2018 |
| Democratic Republic of the Congo | 2032 | 2021 | 2032 | 2021 |
| Djibouti | 2031 | 2021 | 2031 | 2021 |
| Egypt | 2020 | 2004 | 2019 | 2004 |
| Equatorial Guinea | 2033 | 2021 | 2033 | 2021 |
| Ethiopia | 2030 | 2020 | 2028 | 2017 |
| Gabon | 2033 | 2022 | 2033 | 2022 |
| Ghana | 2020 | 2017 | 2019 | 2017 |
| Guinea | 2031 | 2021 | 2032 | 2021 |
| Guinea Bissau | 2034 | 2018 | 2031 | 2018 |
| Kenya | 2028 | 2021 | 2025 | 2018 |
| Liberia | 2032 | 2021 | 2030 | 2018 |
| Madagascar | 2028 | 2021 | 2026 | 2019 |
| Malawi | 2033 | 2020 | 2030 | 2018 |
| Mali | 2032 | 2020 | 2030 | 2018 |
| Mozambique | 2034 | 2022 | 2032 | 2020 |
| Niger | 2027 | 2018 | 2024 | 2017 |
| Nigeria | 2034 | 2023 | 2032 | 2019 |
| Senegal | 2033 | 2020 | 2034 | 2019 |
| Sierra Leone | 2026 | 2015 | 2026 | 2015 |
| South Sudan | 2031 | 2020 | 2031 | 2020 |
| Sudan | 2035 | 2026 | 2034 | 2024 |
| Tanzania | 2034 | 2024 | 2031 | 2018 |
| The Gambia | 2033 | 2022 | 2033 | 2022 |
| Togo | 2016 | 2006 | 2016 | 2006 |
| Uganda | 2033 | 2023 | 2031 | 2019 |
| Zambia | 2033 | 2022 | 2033 | 2022 |
| Zimbabwe | 2033 | 2020 | 2033 | 2021 |
The elimination years shown represent the calendar year when 100% of IUs are predicted to have achieved elimination. For each method, the elimination years were calculated for the model-generated site-specific 95% elimination probability thresholds (EP Th) as well as for the WHO 1% threshold. The results are for the current MDA plus supplemental VC coverages (i.e., for the MDA1 intervention scenario). The sub-Saharan countries not implementing MDA as of 2015 were assumed to start MDA in 2016
Number of countries predicted to achieve elimination in each period under current (MDA1) and remedial intervention strategies. See Table 2 for a description of each intervention strategy
| MDA1 | MDA2 | MDA3 | MDA4 | Bi-MDA1 | Bi-MDA2 | Bi-MDA3 | Bi-MDA4 | IDA1 | IDA2 | IDA3 | IDA4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| By 2020 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 5 |
| 2021–2025 | 4 | 1 | 1 | 1 | 21 | 23 | 30 | 31 | 32 | 32 | 32 | 31 |
| 2026–2030 | 8 | 8 | 11 | 11 | 11 | 9 | 2 | 1 | – | – | – | – |
| After 2030 | 21 | 24 | 21 | 21 | – | – | – | – | – | – | – | – |
Fig. 6Timelines to the elimination of lymphatic filariasis (LF) from sub-Saharan Africa under various intervention strategies. Distributions of calendar years when LF elimination is predicted to be achievable in sub-Saharan Africa under the 12 considered intervention scenarios (see Table 2). These values were calculated by pooling together model-predicted country-specific LF elimination years. The country-specific LF elimination years were calculated as the year by which community-level mf prevalences in all selected spatially representative sites from a given country are predicted to be reduced below their respective 95% elimination probability thresholds (see Table 3). The horizontal line indicates the year 2020 — the target year set for global LF elimination. The error bars show the 2.5th and 97.5th percentile values
Fig. 7Variability in country-specific timelines to lymphatic filariasis (LF) elimination in sub-Saharan Africa. Distributions of the calendar years of LF elimination are shown for 6 out of the 12 considered remedial intervention scenarios (see Table 2). Countries are depicted in the graphs ranked by the year of elimination. Note that some countries are able to meet elimination by 2020 under their current strategy, and so would not need consideration of alternative strategies (Egypt, Ghana, and Togo). The results are shown for MDA1 and MDA4 (a and b), Bi-MDA1 and Bi-MDA4 (c and d), and IDA1 and IDA4 (e and f) (see Table 2 for descriptions). The left panel plots are for the current coverages of MDA and VC, while the right panel ones are for optimal 80% coverages for both. The widths of the boxplots denote the 25th and 75th percentile values of the calendar years shown on the x-axis. The vertical lines indicate the year 2020 — the target year set for global LF elimination (red) and the continental-wide model-predicted median elimination year for each strategy (blue). The whiskers show the 90% confidence interval computed using the 5th and 95th percentile values